FDA Approves Tecentriq Hybreza Anti-PD-(L)1 Cancer Immunotherapy
Genentech announced the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs). The first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection for patients in the United States.
- Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes, compared with 30-60 minutes for standard IV infusion of Tecentriq (atezolizumab).
- It will be available for all IV indications of Tecentriq approved for adults in the U.S., including certain types of lung, liver, skin, and soft tissue cancer.
Source: Genentech
